Maira A Castañeda-Avila1, Erick Suárez-Pérez1, Raúl Bernabe-Dones2, Elizabeth R Unger3, Gitika Panicker3, Ana P Ortiz4. 1. Department of Biostatistics and Epidemiology, Graduate School of Public Health, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico. 2. Department of Biology, Faculty of Natural Sciences, University of Puerto Rico, Río Piedras Campus, Puerto Rico. 3. Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Department of Biostatistics and Epidemiology, Graduate School of Public Health, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; University of Puerto Rico Cancer Control and Population Sciences Program, University of Puerto Rico Comprehensive Cancer Center.
Abstract
OBJECTIVE: There is a high prevalence of human papillomavirus (HPV) infection in Puerto Rico, but little is known about the prevalence of Chlamydia trachomatis (CT) infection in healthy Puerto Rican women. Thus we aimed to evaluate the seroprevalence and association and the association between HPV and CT. METHODS: This was a secondary data analysis from a cross-sectional, populationbased, study of HPV infection in women aged 16-64 years in Puerto Rico (2010-2013). Enzyme-linked immunosorbent assays (ELISA) were used to detect serum antibodies to CT and HPV. Logistic regression models were used to estimate the odds ratio (OR) for the association between HPV and CT serostatus. RESULTS: The study included 524 women; mean age was 42 years. Overall, 97 (18.5%) women were CT-seropositive, 251 (47.0%) were HPV seropositive, and 57 (10.9%) had antibodies for both CT and HPV. Women who were CT-seropositive were more likely (p<0.05) to also be seropositive to any HPV type (ORadjusted: 1.7, IC 95% =1.1, 2.6), HPV 16/18 (ORadjusted: 1.6, IC 95% =1.0, 2.6) and HPV 6/11 (ORadjusted: 1.6, IC 95% =1.1, 2.6) than those CT-seronegative, after adjusting for possible confounding factors. CONCLUSION: Given the association between CT and HPV seropositivity, longitudinal studies to evaluate whether CT infection influences HPV incidence and persistence in this group are warranted.
OBJECTIVE: There is a high prevalence of humanpapillomavirus (HPV) infection in Puerto Rico, but little is known about the prevalence of Chlamydia trachomatis (CT) infection in healthy Puerto Rican women. Thus we aimed to evaluate the seroprevalence and association and the association between HPV and CT. METHODS: This was a secondary data analysis from a cross-sectional, populationbased, study of HPV infection in women aged 16-64 years in Puerto Rico (2010-2013). Enzyme-linked immunosorbent assays (ELISA) were used to detect serum antibodies to CT and HPV. Logistic regression models were used to estimate the odds ratio (OR) for the association between HPV and CT serostatus. RESULTS: The study included 524 women; mean age was 42 years. Overall, 97 (18.5%) women were CT-seropositive, 251 (47.0%) were HPV seropositive, and 57 (10.9%) had antibodies for both CT and HPV. Women who were CT-seropositive were more likely (p<0.05) to also be seropositive to any HPV type (ORadjusted: 1.7, IC 95% =1.1, 2.6), HPV 16/18 (ORadjusted: 1.6, IC 95% =1.0, 2.6) and HPV 6/11 (ORadjusted: 1.6, IC 95% =1.1, 2.6) than those CT-seronegative, after adjusting for possible confounding factors. CONCLUSION: Given the association between CT and HPV seropositivity, longitudinal studies to evaluate whether CTinfection influences HPV incidence and persistence in this group are warranted.
Authors: Hans-Ulrich Bernard; Robert D Burk; Zigui Chen; Koenraad van Doorslaer; Harald zur Hausen; Ethel-Michele de Villiers Journal: Virology Date: 2010-03-05 Impact factor: 3.616
Authors: Kate Russell; Eileen F Dunne; Alex R Kemper; Rowena J Dolor; Elizabeth R Unger; Gitika Panicker; Lauri E Markowitz; Emmanuel B Walter Journal: Vaccine Date: 2015-03-03 Impact factor: 3.641
Authors: Ana Patricia Ortiz; Edmir Marrero; Cristina Muñoz; Cynthia M Pérez; Guillermo Tortolero-Luna; Josefina Romaguera; Nahir Rodríguez; Andrea González-Falero; Joel Palefsky; Erick Suárez Journal: P R Health Sci J Date: 2015-09 Impact factor: 0.705
Authors: Beata Łój; Agnieszka Brodowska; Sylwester Ciecwiez; Iwona Szydłowska; Jacek Brodowski; Marek Łokaj; Andrzej Starczewski Journal: Ann Agric Environ Med Date: 2016-09 Impact factor: 1.447
Authors: Marcia L Shew; J Dennis Fortenberry; Wanzhu Tu; Beth E Juliar; Byron E Batteiger; Brahim Qadadri; Darron R Brown Journal: Arch Pediatr Adolesc Med Date: 2006-02
Authors: Laura J Viens; S Jane Henley; Meg Watson; Lauri E Markowitz; Cheryll C Thomas; Trevor D Thompson; Hilda Razzaghi; Mona Saraiya Journal: MMWR Morb Mortal Wkly Rep Date: 2016-07-08 Impact factor: 17.586
Authors: Xavier Castellsagué; Michael Pawlita; Esther Roura; Núria Margall; Tim Waterboer; F Xavier Bosch; Silvia de Sanjosé; Carlos Alberto Gonzalez; Joakim Dillner; Inger T Gram; Anne Tjønneland; Christian Munk; Valeria Pala; Domenico Palli; Kay-Tee Khaw; Ruanne V Barnabas; Kim Overvad; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Guy Fagherazzi; Rudolf Kaaks; Annekatrin Lukanova; Annika Steffen; Antonia Trichopoulou; Dimitrios Trichopoulos; Eleni Klinaki; Rosario Tumino; Carlotta Sacerdote; Amalia Mattiello; H B As Bueno-de-Mesquita; Petra H Peeters; Eiliv Lund; Elisabete Weiderpass; J Ramón Quirós; María-José Sánchez; Carmen Navarro; Aurelio Barricarte; Nerea Larrañaga; Johanna Ekström; Maria Hortlund; David Lindquist; Nick Wareham; Ruth C Travis; Sabina Rinaldi; Massimo Tommasino; Silvia Franceschi; Elio Riboli Journal: Int J Cancer Date: 2014-01-06 Impact factor: 7.396
Authors: Fleur van Aar; Sofie H Mooij; Marianne A B van der Sande; Chris J L M Meijer; Audrey J King; Dominique W M Verhagen; Titia Heijman; Roel A Coutinho; Maarten F Schim van der Loeff Journal: BMC Infect Dis Date: 2014-12-31 Impact factor: 3.090